Specialist Working Group for Haematology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE INTRAVENOUS IMMUNOGLOBULIN IN (A) Administrative) AUSTRALIA, SECOND EDITION (CRITERIA) (B) Progressive (C) Programmed Condition Neonatal haemochromatosis (NH) Neonatal haemochromatosis (NH) Name Specialty Haematology Haematology Chapter 5 5 Specific Conditions Level of Evidence of probable benefit (). Evidence of probable benefit (). Evidence Justification for A trial compared the impact of IVIg on pregnancy A trial compared the impact of intravenous Addition of evidence with successful use of IVIg Evidence immunoglobulin (IVIg) on pregnancy outcome together with exchange transfusion. (A) outcome of women whose most recent Category of women whose most recent pregnancy had pregnancy had resulted in NH with historical resulted in NH with historical controls controls (randomly selected previously affected (randomly selected previously affected pregnancies). All 15 pregnancies resulted in live pregnancies). All 15 pregnancies resulted in live births. NH was diagnosed in 11 but responded to births. NH was diagnosed in 11 but responded medical treatment. By contrast, there were 2 to medical treatment. By contrast, there were two successful outcomes in controls (Biotext successful outcomes in controls (Biotext 2004). 2004). Rand et al (2009) describes successful treatment of NH in neonates using exchange transfusion and IVIg. Description and NH manifests in the foetus and newborn and is Ne NH manifests in the foetus and newborn, Diagnostic characterised by abnormal accumulation of iron and is characterised by abnormal accumulation Criteria in the liver and extra-hepatic tissues. Affected of iron in the and extra-hepatic tissues. neonates present with fulminant liver failure, Affected neonates present with fulminant liver usually in the context of a history of prematurity, failure, usually in the context of a history of
Specialist Working Group for Haematology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF INTRAVENOUS IMMUNOGLOBULIN IN AUSTRALIA, SECOND EDITION (CRITERIA) PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE (A) Administrative) (B) Progressive (C) Programmed Condition Name Neonatal haemochromatosis (NH) Neonatal haemochromatosis (NH) Specialty Haematology Haematology Chapter 5 5 Specific Conditions Level of Evidence Evidence of probable benefit (). Evidence of probable benefit (). Justification for Evidence Category A trial compared the impact of IVIg on pregnancy outcome of women whose most recent pregnancy had resulted in NH with historical controls (randomly selected previously affected pregnancies). All 15 pregnancies resulted in live births. NH was diagnosed in 11 but responded to medical treatment. By contrast, there were 2 successful outcomes in controls (Biotext 2004). A trial compared the impact of intravenous immunoglobulin (IVIg) on pregnancy outcome of women whose most recent pregnancy had resulted in NH with historical controls (randomly selected previously affected pregnancies). All 15 pregnancies resulted in live births. NH was diagnosed in 11 but responded to medical treatment. By contrast, there were two successful outcomes in controls (Biotext 2004). Rand et al (2009) describes successful treatment of NH in neonates using exchange transfusion and IVIg. Addition of evidence with successful use of IVIg together with exchange transfusion. (A) Description and Diagnostic Criteria NH manifests in the foetus and newborn and is characterised by abnormal accumulation of iron in the liver and extra-hepatic tissues. Affected neonates present with fulminant liver failure, usually in the context of a history of prematurity, Ne NH manifests in the foetus and newborn, and is characterised by abnormal accumulation of iron in the and extra-hepatic tissues. Affected neonates present with fulminant liver failure, usually in the context of a history of
neonatal-haemochromatosis%28nh%29_0.DOCX